Morgan Stanley

Morgan Stanley announced record net revenues of $21.3 billion and EPS of $3.46 for the second quarter of 2026, driven by strong performance across its Institutional Securities and Wealth Management divisions.

Morgan Stanley announced a 15% dividend increase to $1.15 per share and the reauthorization of a $20 billion common equity share repurchase program.

Morgan Stanley announced record net revenues of $20.6 billion and EPS of $3.43 for the first quarter of 2026, driven by strong performance across its Institutional Securities and Wealth Management divisions.

Morgan Stanley announced CEO Edward Pick's 2025 compensation of $45 million, reflecting record net revenues, earnings per share, and strong shareholder returns.

Morgan Stanley reported outstanding financial results for the fourth quarter and full year 2025, driven by record revenues, strong earnings per share, and robust returns on tangible common equity across its integrated businesses.

Morgan Stanley reports record net revenues of $18.2 billion and diluted EPS of $2.80 for Q3 2025, driven by robust performance across all businesses.

Morgan Stanley reported robust third-quarter 2025 results, with net income surging 45% to $4.6 billion and diluted EPS rising 49% to $2.80, driven by strong performance across all business segments.

Morgan Stanley reported robust second-quarter 2025 results with net revenues up 12% to $16.8 billion and net income rising 15% to $3.5 billion.

Morgan Stanley announced a 17% increase in net revenues and a 26% increase in net income for the quarter ended March 31, 2025, driven by strong performance in Equity and Investment Banking.

Morgan Stanley's Q3 2024 results show a 16% increase in net revenues and a 32% increase in net income compared to the same period last year, driven by strong performance across all business segments.

Morgan Stanley's Q2 2024 results show a 12% increase in net revenues and a 41% increase in net income compared to the same period last year, driven by strong performance in Institutional Securities and Wealth Management.

Morgan Stanley announced a robust first quarter for 2024, with net revenues of $15.1 billion and net income of $3.4 billion, demonstrating strong performance across all business segments.

Morgan Stanley announced robust financial results for the year ended December 31, 2025, with significant increases in net revenues, net income, and diluted earnings per share, alongside improved efficiency and capital strength.

Morgan Stanley's 2024 10-K filing reveals a strong financial year with increased net revenues and net income, driven by solid performance across its Institutional Securities, Wealth Management, and Investment Management segments.

Morgan Stanley's 10-K filing details the registration of its common stock, preferred stock depositary shares, and medium-term notes under the Securities Exchange Act of 1934.

Mitsubishi Ufj Financial Group Inc reported changes in beneficial ownership of Morgan Stanley common stock on July 30, 2026.

Mary L Schapiro, a Director of Morgan Stanley, sold 1,000 shares of common stock on July 28, 2026 for $212.06 per share.

Sharon Yeshaya, Chief Financial Officer of Morgan Stanley, sold 15,554 shares of common stock on July 16, 2026 for $222.51 per share.

Michael A. Pizzi, Head Technology & Operations of Morgan Stanley, sold 24,165 shares of common stock on July 17, 2026.

Dennis M. Nally, a Director at Morgan Stanley, reported transactions involving the acquisition of restricted and deferred stock units.

Rayford Wilkins Jr., a Director at Morgan Stanley, acquired 1,309.777 shares of Common Stock on June 1, 2026, as part of the Directors' Equity Capital Accumulation Plan.

Morgan Stanley announced record revenues, net income, and EPS for 2025, driven by strong performance across its diversified business segments and strategic execution.

Morgan Stanley has filed a definitive proxy statement with the Securities and Exchange Commission.

Morgan Stanley has filed a definitive proxy statement with the SEC.

Morgan Stanley's proxy statement highlights a record year in net revenues and a successful leadership transition, setting the stage for future growth.

Morgan Stanley's Board of Directors recommends shareholders vote for management proposals, including executive compensation, and against shareholder proposals related to lobbying transparency and clean energy financing ratios.

Morgan Stanley has filed a definitive proxy statement with the Securities and Exchange Commission.

Burford Capital's latest 13F-HR filing discloses its investment holdings as of the reporting date.

Invesco's recent 13F-HR filing discloses changes in their investment portfolio, providing insights into their holdings as of the filing date.

BlackRock's latest 13F filing discloses adjustments to its investment portfolio, including new positions in Bullfrog AI and Titan Pharmaceuticals.

Calamos Advisors recently filed its 13F with the SEC, revealing changes in its investment portfolio.

The latest 13F filing reveals key holdings and investment strategies.

A comprehensive overview of a fund's holdings has been filed with the SEC, detailing positions in various securities.

Mitsubishi UFJ Financial Group (MUFG) has notified Morgan Stanley of its intent to resume share sales under a previously suspended plan, with sales set to recommence on July 30, 2026.

Mitsubishi UFJ Financial Group (MUFG) has amended its investor agreement with Morgan Stanley, extending standstill and preemptive rights provisions to October 13, 2028.

Mitsubishi UFJ Financial Group, Inc. filed an amendment to its Schedule 13D, disclosing a 23.91% beneficial ownership stake in Morgan Stanley as of November 3, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed a Schedule 13G, reporting beneficial ownership of less than 5% of the Auction Preferred Stock of Eaton Vance Ltd Duration Income Fund.

Morgan Stanley and its subsidiary Morgan Stanley Smith Barney LLC have filed a Schedule 13G, reporting beneficial ownership of less than 5% of MFS Charter Income Trust's common stock as of June 30, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G, indicating a reduction in their beneficial ownership of CervoMed Inc. common stock to below the 5% threshold.

Morgan Stanley has filed a Schedule 13G, indicating it no longer beneficially owns more than five percent of the common stock of MFS Investment Grade Municipal Trust.

Morgan Stanley has filed a Schedule 13G reporting a 7.5% beneficial ownership stake in Zepp Health Corp.

Morgan Stanley has filed an amendment indicating it no longer beneficially owns more than five percent of Terns Pharmaceuticals, Inc. common stock.